Related references
Note: Only part of the references are listed.Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
Jason K. Sicklick et al.
NATURE MEDICINE (2019)
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial
Jordi Rodon et al.
NATURE MEDICINE (2019)
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial
Rachna T. Shroff et al.
JAMA ONCOLOGY (2019)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert M. Samstein et al.
NATURE GENETICS (2019)
Tumour heterogeneity and resistance to cancer therapies
Ibiayi Dagogo-Jack et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma
Eirini Pectasides et al.
CANCER DISCOVERY (2018)
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
Milind Javle et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Blood-based genomic profiling of cell-free tumor DNA (ctDNA) in patients with biliary tract cancer
Lipika Goyal et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Emerging role of precision medicine in biliary tract cancers
James M. Bogenberger et al.
NPJ PRECISION ONCOLOGY (2018)
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Aaron M. Goodman et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study
Talia Golan et al.
ONCOLOGIST (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
New Horizons for Precision Medicine in Biliary Tract Cancers
Juan W. Valle et al.
CANCER DISCOVERY (2017)
Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes
Catherine C. Coombs et al.
CELL STEM CELL (2017)
Biliary Cancer: Utility of Next-Generation Sequencing for Clinical Management
Milind Javle et al.
CANCER (2016)
Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design
Jason K. Sicklick et al.
CANCER AND METASTASIS REVIEWS (2016)
Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study
Jennifer J. Wheler et al.
CANCER RESEARCH (2016)
Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience
Maria Schwaederle et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Response of BRCA1- mutated gallbladder cancer to olaparib: A case report
Yuan Xie et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials
Maria Schwaederle et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA
Richard B. Lanman et al.
PLOS ONE (2015)
Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
Giulio Genovese et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma
D. P. S. Sohal et al.
ANNALS OF ONCOLOGY (2013)
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
Garrett M. Frampton et al.
NATURE BIOTECHNOLOGY (2013)
Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer
L. H. Jensen et al.
ANNALS OF ONCOLOGY (2012)
Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative
Apostolia-Maria Tsimberidou et al.
CLINICAL CANCER RESEARCH (2012)
Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study
Jeeyun Lee et al.
LANCET ONCOLOGY (2012)
Advances in the treatment of metastatic or unresectable biliary tract cancer
J. W. Valle
ANNALS OF ONCOLOGY (2010)
Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan
T. Okusaka et al.
BRITISH JOURNAL OF CANCER (2010)
Genetics of Biliary Tract Cancers and Emerging Targeted Therapies
Aram F. Hezel et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer.
Juan Valle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma:: a GERCOR study
T André et al.
ANNALS OF ONCOLOGY (2004)
Share Paper
